NASDAQ · Biotechnology · USD
Nkarta, Inc. (NKTX) Stock Analysis
Nkarta, Inc. (NKTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
NKTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.76
- Previous Close
- $1.74
- Day's Range
- 1.74–1.82
- 52-Week Range
- 1.70–3.72
- Volume
- 1.09M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.94
Valuation
- Market Cap
- $125.34M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −1.58
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$104.08M
- Shares Outstanding
- 71.62M
- 1-Year Return
- −26.78%
Dividend and dates
- Earnings Date
- November 10, 2026estimated
- Avg Volume
- 668.73K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, NKTX closed at $1.75, −26.78% over 1 year.
Nkarta, Inc. (NKTX) has a market capitalization of $125.34M.
In fiscal 2025, NKTX reported revenue of $0.00.
NKTX Stock Return by Calendar Year
Nkarta, Inc. (NKTX) return since Jul 2020: what $10,000 became
- 1 year
- $10,000 $7,322
- −26.78%
- 5 years
- $10,000 $1,023
- −89.77%
- Since Jul 2020
- $10,000 $365
- −96.35%
If you had invested $10,000 in Nkarta, Inc. (NKTX) at the close on July 10, 2020, the earliest close on record here, it would have been worth $365 at the close on October 21, 2026: −96.35% in total, −40.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −5.41% |
| 2025 | −25.70% |
| 2024 | −62.27% |
| 2023 | +10.18% |
| 2022 | −60.98% |
| 2021 | −75.03% |
| 2020 (partial year) | +28.33% |
As of October 21, 2026.
NKTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$104.08M | — |
| 2024 | $0.00 | −$108.79M | — |
| 2023 | $0.00 | −$117.50M | — |
| 2022 | $0.00 | −$113.84M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$122.00M | −$104.08M | — |
| 2024 | $0.00 | — | −$128.19M | −$108.79M | — |
| 2023 | $0.00 | — | −$131.65M | −$117.50M | — |
| 2022 | $0.00 | — | −$118.96M | −$113.84M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
MarketBeatNkarta to Participate in September Investor Conferences
YahooNkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
YahooNkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
SeekingAlphaStifel Maintains Buy on Nkarta, Lowers Price Target to $10
BenzingaHC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B